Immunotherapy

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Wednesday, October 19, 2016

Five things for pharma marketers to know: Wednesday, October 19, 2016

By

Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market

Five things for pharma marketers to know: Friday, June 10, 2016

Five things for pharma marketers to know: Friday, June 10, 2016

By

FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec

Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

By

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Five things for pharma marketers to know: Friday, February 26, 2016

Five things for pharma marketers to know: Friday, February 26, 2016

By

Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO

Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

By

The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.

OPINION

Email Newsletters